<DOC>
	<DOCNO>NCT02140125</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetics single subcutaneous dose ASP2408 non-elderly healthy adult male subject . The pharmacodynamics ASP2408 also evaluate .</brief_summary>
	<brief_title>A Study Evaluate Safety ASP2408 After Subcutaneous Administration Healthy Male Subjects</brief_title>
	<detailed_description>This clinical study conduct double-blind , placebo-controlled , single ascend subcutaneous dose study . As show table , study conduct use 3 cohort , total 24 subject randomly assign ( 18 subject receive ASP2408 6 subject receive placebo ) . Each cohort consist 8 subject , randomly assign either ASP2408 group placebo group ratio 3 1 . Each subject need hospitalize Day 8 ( start date study drug administration regard Day 1 ) observe Day 90 . The investigator subinvestigator carefully observe subject sign symptom adverse event .</detailed_description>
	<criteria>BMI ( screen ) : ≥ 17.6 kg/m2 , &lt; 26.4 kg/m2 Healthy , judge investigator subinvestigator base result medical examination ( subjective symptom objective finding ) test obtain screen period hospitalization ( Day −2 ) immediately study drug administration Subjects agree use effective contraception 90 day study drug administration Received investigational drug clinical postmarketing study within 120 day study schedule receive investigational drug Donated 400 mL whole blood within 90 day study period screening , 200 mL whole blood within 30 day , blood component within 14 day study , schedule donate 400 mL whole blood blood component Received medication within 7 day hospitalization ( Day −2 ) schedule receive medication Received systemic medication influence immune function ( e.g. , steroid , tacrolimus hydrate , anticancer drug , biological product ) within 365 day study drug administration Received live virus vaccine ( e.g. , BCG , polio , measles , rubella ) within 180 day study drug administration , agree receive vaccine 180 day study drug administration Received live virus vaccine ( e.g. , BCG , polio , measles , rubella ) within 180 day study drug administration , agree receive vaccine 180 day study drug administration A deviation normal range blood pressure , pulse rate , body temperature , standard 12lead ECG ( see Table 3.31 ) screen day study drug administration ( Day −1 ) Any deviation normal range laboratory test study drug administration Failure meet criterion standard 12lead ECG QT assessment screen A positive result tuberculosis test Concurrent history drug allergy , anaphylaxis , severe allergic reaction Upper GI disease Concurrent previous hepatic disease ( e.g. , viral hepatitis druginduced liver injury ) Concurrent previous heart disease ( e.g. , congestive heart failure , angina pectoris , arrhythmia require treatment ) Concurrent previous respiratory disease ( e.g. , bronchial asthma chronic bronchitis ; except history childhood asthma ) Previous operation gut excision Concurrent previous renal disease ( e.g. , acute renal failure , glomerulonephritis , interstitial nephritis ; except history calculus ) Concurrent previous endocrine disease ( e.g. , hyperthyroid , abnormality growth hormone ) Concurrent previous cerebrovascular disorder ( e.g. , cerebral infarction ) Concurrent previous malignant tumor Concurrent previous serious infection ( e.g. , sepsis , pneumonia require hospitalization , pyelonephritis )</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>ASP2408</keyword>
</DOC>